Tekla Capital Management’s Whitehawk Therapeutics WHWK Stock Holding History

Tekla Capital Management’s Portfolio WHWK Stock Details WHWK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-17,170	Closed	-$322K	–	223
2020 Q2	$322K	Hold	17,170	–	–	0.01%	214
2020 Q1	$142K	Hold	17,170	–	–	0.01%	207
2019 Q4	$161K	Hold	17,170	–	–	0.01%	207
2019 Q3	$175K	Sell	17,170 -32,163	-65%	-$356K	0.01%	183
2019 Q2	$673K	Hold	49,333	–	–	0.03%	176
2019 Q1	$667K	Sell	49,333 -1,667	-3%	-$71.7K	0.03%	175
2018 Q4	$1.3M	Hold	51,000	–	–	0.06%	150
2018 Q3	$2.36M	Hold	51,000	–	–	0.09%	143
2018 Q2	$3.17M	Buy	+51,000	New	+$3.08M	0.12%	112

Other funds holding WHWK

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

JIC

Johnson Investment Counsel Cincinnati, Ohio $12.4B AUM 17.21% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Tekla Capital Management's WHWK Position: Q3 2020 in Review

Tekla Capital Management sold out of Whitehawk Therapeutics (WHWK) in Q3 2020, closing a stake of 17,170 shares — an estimated $322K sold.

Tekla Capital Management first reported a position in WHWK in Q2 2018 and held it in 9 quarters. The position peaked at $3.17M in Q2 2018. 33 funds tracked by Wall St. Rank hold WHWK as of Q3 2020.

Tekla Capital Management reported no remaining Whitehawk Therapeutics position as of Q3 2020 after selling out during the quarter.
Tekla Capital Management sold 17,170 Whitehawk Therapeutics shares in Q3 2020, an estimated $322K.
Tekla Capital Management first reported a position in Whitehawk Therapeutics in Q2 2018 and held it in 9 quarters.
Tekla Capital Management's Whitehawk Therapeutics position peaked at $3.17M in Q2 2018.
33 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q3 2020.

Based on Tekla Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.